Results 61 to 70 of about 26,462 (230)

Long non-coding RNA metallothionein 1 pseudogene 3 promotes p2y12 expression by sponging miR-126 to activate platelet in diabetic animal model

Platelets, 2019
Platelet hyperaggregation and hypercoagulation are associated with increase of thrombogenic risk, especially in patients with type 2 diabetes (T2D).
Ming Zhou, Meng Gao, Yanwei Luo, Rong Gui, Hongwen Ji   +4 more
doaj   +1 more source

NICHE OF PRASUGREL AMONG OTHER PLATELET P2Y12-RECEPTOR INHIBITORS

Атеротромбоз, 2017
Platelet P2Y12-receptor inhibitors are ranked 2nd in terms of administration frequency among antiplatelet agents (after acetylsalicylic acid). Administration of such drugs is mandatory in conditions characterized by increased activation of platelets ...
P. S. LAGUTA, E. P. PANCHENKO
doaj   +1 more source

Consolidation of P2Y12 Testing While Maintaining Quality and Turnaround Time [PDF]

, 2017
Objective: To consolidate the test performed at 2 different locations at 1, thereby improving cost effectiveness while maintaining quality and result turnaround time.https://jdc.jefferson.edu/patientsafetyposters/1059/thumbnail ...
Gong, MD, Jerald Z., Jagannathan, MBBS, Geetha   +1 more
core   +1 more source

Population Pharmacokinetics of Ticagrelor during Veno‐Arterial ECMO in Acute Coronary Syndrome: Model‐Informed Dosing Simulations

Clinical Pharmacology &Therapeutics, EarlyView.
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang, Kyoung Lok Min, Seungwon Yang, Jongsung Hahn, Dasohm Kim, Byung Hak Jin, Soon Uk Chae, Soo Kyung Bae, Jin Wi, Min Jung Chang   +9 more
wiley   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Structure of the human P2Y12 receptor in complex with an antithrombotic drug [PDF]

Nature, 2014
P2Y receptors (P2YRs), a family of purinergic G-protein-coupled receptors (GPCRs), are activated by extracellular nucleotides. There are a total of eight distinct functional P2YRs expressed in human, which are subdivided into P2Y1-like receptors and P2Y12-like receptors.
Kaihua, Zhang, Jin, Zhang, Zhan-Guo, Gao, Dandan, Zhang, Lan, Zhu, Gye Won, Han, Steven M, Moss, Silvia, Paoletta, Evgeny, Kiselev, Weizhen, Lu, Gustavo, Fenalti, Wenru, Zhang, Christa E, Müller, Huaiyu, Yang, Hualiang, Jiang, Vadim, Cherezov, Vsevolod, Katritch, Kenneth A, Jacobson, Raymond C, Stevens, Beili, Wu, Qiang, Zhao   +20 more
openaire   +2 more sources

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock – a Case Series

Cellular Physiology and Biochemistry, 2017
Background/Aims: Patients with acute coronary syndromes (ACS) presenting with cardiogenic shock (CS) are at particular risk for death and adverse cardiac events.
Michal Droppa, Oliver Borst, Dominik Rath, Karin Müller, Meinrad Gawaz, Deepak L. Bhatt, Tobia Geisler   +6 more
doaj   +1 more source

ADP-Mediated Upregulation of Expression of CD62P on Human Platelets Is Critically Dependent on Co-Activation of P2Y1 and P2Y12 Receptors

Pharmaceuticals, 2020
This study probed the differential utilization of P2Y1 and P2Y12 receptors in mobilizing CD62P (P-selectin) from intracellular granules following activation of human platelets with adenosine 5′-diphosphate (ADP, 100 µmol·L−1) Platelet-rich plasma (PRP ...
Ronald Anderson, Annette J. Theron, Helen C. Steel, Jan G. Nel, Gregory R. Tintinger   +4 more
doaj   +1 more source